At Matterworks, we envision a future where artificial intelligence seamlessly unlocks the molecular secrets hidden within complex biological data, transforming raw scientific measurements into predictive insights that accelerate life sciences innovation. Our commitment is to bridge the gap between data and actionable understanding, empowering researchers to courageously explore biological frontiers.
We harness advanced AI technologies, including our pioneering Large Spectral Model, to interpret unstructured omic data with unprecedented precision, opening new pathways for discovery in biotechnology and beyond. Through the integration of sophisticated machine learning and proprietary chemical innovations, we seek to revolutionize how molecular data drives scientific progress.
By building scalable, AI-driven platforms and services, Matterworks is dedicated to reshaping life sciences research, enabling a new era of faster, more cost-effective breakthroughs that improve health and deepen knowledge of biological systems on a global scale.
Our Review
We've been tracking Matterworks since their early days, and frankly, we're impressed by how they're tackling one of biotech's messiest problems. While everyone's talking about AI in healthcare, these folks are going deeper — literally into the molecular level where the real mysteries live.
The "Aha" Moment for Biotech
Here's what caught our attention: Matterworks built something called a Large Spectral Model (LSM), which is basically ChatGPT for mass spectra data. If that sounds like gibberish, think of it this way — they're teaching AI to read the chemical fingerprints of biological samples and predict what'll happen next.
Most biotech companies collect mountains of data but struggle to make sense of it all. Matterworks is saying, "Hold our coffee, we've got this." Their AI doesn't just analyze the data; it finds patterns that human scientists might miss entirely.
Why This Feels Different
We've seen plenty of AI-for-science startups come and go, but Matterworks has something special brewing. Their founding team isn't just machine learning experts or just biology nerds — they're both. That interdisciplinary approach shows in their product.
Plus, they're not just building software. They've developed their own chemistry reagents for real-time metabolomics, which means they control more of the data pipeline. That's smart positioning in a field where data quality makes or breaks everything.
The Funding Reality Check
Their Series A in June 2025 tells us the smart money is paying attention. Lewis & Clark Partners and OMX Ventures don't write checks lightly, especially in biotech where timelines are brutal and success isn't guaranteed.
With under 25 employees and revenue below $5 million, they're still very much in startup mode. But that's actually encouraging — it means they're focused on building the right foundation instead of scaling prematurely.
Who Should Care
If you're a biotech researcher drowning in unstructured data or a pharma company looking to speed up discovery timelines, Matterworks deserves a conversation. Their model-as-a-service approach means you don't need to hire a team of AI experts to benefit from their platform.
We're curious to see how they'll handle the inevitable growing pains as demand scales. But for now, they're solving a real problem with genuine innovation — and that's always worth watching.
Features
AI-powered analysis of complex, unstructured biological data
Large Spectral Model (LSM) platform for omic data interpretation
Prediction of biological outcomes from molecular data
Model-as-a-Service offering for scalable application
Proprietary chemistry reagents for real-time quantitative metabolomics
FAQs
Ploy was founded in 2024.
Biology has always been an empirical science. We're making it a science of prediction. Matterworks builds foundation models for biochemical omics — the next frontier in AI-powered research. Our platform, Pyxis, applies large-scale spectral modeling to mass spectrometry data, giving pharma and biotech teams the power to predict biological properties, classify disease states, and anticipate outcomes across the entire R&D lifecycle. From self-service exploration to lab services and enterprise partnerships, we work with pharma and biotech organizations to bring predictive biology to every stage of R&D.
Ernst and Young
Lemni
Georgia Tech
Freepik
Upstart
CompliantChatGPT
Brain.fm
SurveyMonkey Genius
